A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

Phase 1 Not yet recruiting 36 enrolled Design Therapeutics, Inc.

RandomizedCrossoverDouble-blindTreatment

Summary

This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.

Timeline

Start: 2025-02
Primary completion: 2025-09
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DT-216P2	Unknown	—	Subcutaneous

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

Summary

Timeline

Drugs

Indications